Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

LocomoGene, Inc. is a Japanese private company located in Yokohama that develops novel medicines based on genome research.

Proyecto de Biomedicina CIMA SL is a holding company engaged in the provision of product licensing and intellectual property rights management services. It holds patents generated by the Centro de Investigacion Medica Aplicada, which have indications across the clinical fields of oncology, hepatology, dermatology, and gene therapy. The company was founded in June 2003 and is headquartered in Pamplona, Spain.

Central Institute for Experimental Animals (CIEA) (実験動物中央研究所) is a research center for experimental animals in Japan. It was founded by Tatsuji Nomura in 1952 with the mission of improving the level of biomedical research.

Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was founded in 1997 and is headquartered in San Mateo, California.

Saiye (Suzhou) Biotechnology Co., Ltd, established on 2011-05-27, Business scope includes bioengineering technology development,technical consulting,technology transfer,Technical Services,Research and development of biomedical materials and products;Distribution of experimental equipment;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Wuhan Wellcome Gene Technology Co., Ltd., established on 2017-12-05, Business scope includes licensed projects:Inspection and testing service;Experimental animal management;pharmaceutical production;Drug retail;feed production;Feed additive production;Veterinary drug production;Veterinary drug business;Animal Clinic;Import and export;Technology Import and Export;Import and export agency;Drug import and export;Food import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;New material technology research and development;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Manufacturing of experimental analysis instruments;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Bio-feed R&D;Feed Additive Sales;pet service(No Animal Treatment);Manufacturing of daily chemical products;Sales of daily chemical products;software development;Artificial intelligence basic software development;Artificial intelligence theory and algorithm software development;Artificial intelligence application software development;Artificial intelligence public service platform technical consulting services;Network and Information Security Software Development;Information Technology Consulting Services;internet data service;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Sales of office equipment consumables;Conference and Exhibition Services;Educational Consulting Services(Education and training activities that do not include licensing approval)(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Manufactures and sells pharmaceuticals

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Wuhan Huikangda Technology Co., Ltd., established on 2019-12-24, The scope of business includes professional technical services for experimental animal models;Model Animal Resource Bank Information Technology Services;Gene sequencing professional technical services;Genetic Testing,modify;Laboratory Animal Testing;Animal Inspection and Quarantine Services;Bioengineering and Biomedical Engineering Technology Products,Laboratory Biological Products,laboratory consumables(Does not contain hazardous chemicals),Ι,R&D and sales of Class II medical devices;Medical Research Services and Trial Development;Technical services in the field of biomedicine,technology transfer,technical consulting;Preparation of pharmaceutical intermediates,R & D and sales;Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Involved in licensing projects,It should be operated after obtaining the permission of the relevant department)

ITI Scotland Ltd. is a company set up in 2003 by Scottish Enterprise with the support of the Scottish Executive to identify and commercialise valuable technology-based intellectual assets across three global market sectors: digital media and communications; life sciences and energy.

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden.

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.